A carregar...

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer

The development of human epidermal growth factor 2 (HER2)-directed therapy has resulted in significant improvement in outcomes for patients with early-stage HER2-overexpressing (HER2+) breast cancer. In recent years, newer HER2-directed agents and novel treatment strategies have been developed with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Basho, Reva K., McArthur, Heather L.
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6048669/
https://ncbi.nlm.nih.gov/pubmed/30034547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918775697
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!